NeuroSense Therapeutics has entered into a Securities Purchase Agreement with a single investor and CEO Alon Ben-Noon for a $5 million private placement at $1.25 per share, representing a 25% premium to market price. The offering includes 2.34M ordinary shares, 1.66M pre-funded warrants, and 8M ordinary warrants, with proceeds to be delivered in two tranches by March 2025.The company plans to use the proceeds to advance the clinical development of PrimeC for ALS, support research for Alzheimer's and Parkinson's disease treatments, and fund general corporate purposes. The ordinary warrants are exercisable immediately at $1.25 per share with a five-year term, while pre-funded warrants have a nominal exercise price of $0.0001.The private placement is being conducted under Section 4(a)(2) of the Securities Act exemption, with securities to be registered for resale through a Form F-3 registration statement. The transaction includes standard provisions limiting warrant holders to maximum ownership of 9.99% of outstanding shares after exercise.

NeuroSense Therapeutics has entered into a Securities Purchase Agreement with a single investor and CEO Alon Ben-Noon for a $5 million private placement at $1.25 per share, representing a 25% premium to market price. The offering includes 2.34M ordinary shares, 1.66M pre-funded warrants, and 8M ordinary warrants, with proceeds to be delivered in two tranches by March 2025.The company plans to use the proceeds to advance the clinical development of PrimeC for ALS, support research for Alzheimer's and Parkinson's disease treatments, and fund general corporate purposes. The ordinary warrants are exercisable immediately at $1.25 per share with a five-year term, while pre-funded warrants have a nominal exercise price of $0.0001.The private placement is being conducted under Section 4(a)(2) of the Securities Act exemption, with securities to be registered for resale through a Form F-3 registration statement. The transaction includes standard provisions limiting warrant holders to maximum ownership of 9.99% of outstanding shares after exercise.